Your browser doesn't support javascript.
loading
CiPA challenges and opportunities from a non-clinical, clinical and regulatory perspectives. An overview of the safety pharmacology scientific discussion.
Wallis, Rob; Benson, Charles; Darpo, Borje; Gintant, Gary; Kanda, Yasunari; Prasad, Krishna; Strauss, David G; Valentin, Jean-Pierre.
Afiliación
  • Wallis R; Royal Tunbridge Wells, TN3 9EA, UK. Electronic address: robwallis120@hotmail.com.
  • Benson C; Clinical Phamacology, Eli Lilly and Company, United States.
  • Darpo B; iCardiac Technologies, United States.
  • Gintant G; Department of Integrative Pharmacology, Abbvie, United States.
  • Kanda Y; Division of Pharmacology, National Institute of Health Sciences, 3-25-26 Tonomachi, Kawasaki-ku, Kawasaki, Kanagawa 210-9501, Japan.
  • Prasad K; Medicines and Healthcare Products Regulatory Agency (MHRA), London, UK.
  • Strauss DG; U.S. Food and Drug Administration, Silver Spring, MD, USA.
  • Valentin JP; UCB-Biopharma SPRL, Non-Clinical Development, 1420 Braine L'Alleud, Belgium.
Article en En | MEDLINE | ID: mdl-29958940

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Arritmias Cardíacas / Sociedades Farmacéuticas / Simulación por Computador / Congresos como Asunto / Electrocardiografía Tipo de estudio: Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: J Pharmacol Toxicol Methods Año: 2018 Tipo del documento: Article

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Arritmias Cardíacas / Sociedades Farmacéuticas / Simulación por Computador / Congresos como Asunto / Electrocardiografía Tipo de estudio: Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: J Pharmacol Toxicol Methods Año: 2018 Tipo del documento: Article